BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Plevris N, Fulforth J, Lyons M, Siakavellas SI, Jenkinson PW, Chuah CS, Lucaciu L, Pattenden RJ, Arnott ID, Jones G, Lees CW. Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:1835-1844.e6. [DOI: 10.1016/j.cgh.2020.08.022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Gergely M, Deepak P. Tools for the Diagnosis and Management of Crohn's Disease. Gastroenterol Clin North Am 2022;51:213-39. [PMID: 35595412 DOI: 10.1016/j.gtc.2021.12.003] [Reference Citation Analysis]
2 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022:S0016-5085(22)00078-6. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
3 Lefevre PLC, Dulai PS, Wang Z, Guizzetti L, Feagan BG, Pop A, Yassine M, Shackelton LM, Jairath V, Sandborn WJ, Vande Casteele N. A Clinical Prediction Model to Determine Probability of Response to Certolizumab Pegol for Crohn's Disease. BioDrugs 2021. [PMID: 34951696 DOI: 10.1007/s40259-021-00512-8] [Reference Citation Analysis]
4 . Weitere Evidenz für FC als prognostisch relevantem Biomarker bei Morbus Crohn. Z Gastroenterol 2021;59:1262-3. [DOI: 10.1055/a-1652-8721] [Reference Citation Analysis]
5 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Bouhuys M, Lexmond WS, Dijkstra G, Lobatón T, Louis E, van Biervliet S, Groen H, Guardiola J, Rheenen PV. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open 2021;11:e054154. [PMID: 34732500 DOI: 10.1136/bmjopen-2021-054154] [Reference Citation Analysis]
7 Atreya R, Neurath MF. Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients? J Crohns Colitis 2021;15:697-8. [PMID: 33677523 DOI: 10.1093/ecco-jcc/jjab009] [Reference Citation Analysis]
8 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kennedy NA. Integrating a treat to target approach into clinical practice in 2020. J Gastroenterol Hepatol 2021;36 Suppl 1:6-7. [PMID: 33817849 DOI: 10.1111/jgh.15446] [Reference Citation Analysis]
10 Zou F, Wang X, Glitza Oliva IC, McQuade JL, Wang J, Zhang HC, Thompson JA, Thomas AS, Wang Y. Fecal calprotectin concentration to assess endoscopic and histologic remission in patients with cancer with immune-mediated diarrhea and colitis. J Immunother Cancer 2021;9:e002058. [PMID: 33436487 DOI: 10.1136/jitc-2020-002058] [Cited by in F6Publishing: 10] [Reference Citation Analysis]